Former FDAer Marvin Seife
Jury trial is scheduled for Sept. 17 in Baltimore federal court. The former head of the agency's Division of Generic Drugs pleaded not guilty to two counts of perjury at his June 29 arraignment. The indictment alleges that Seife lied to an FDA investigator and to Rep. Dingell's House Energy and Commerce/Oversight subcommittee about having lunch with two generic company execs, and that he falsely denied having meals paid for by drug company representatives.
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.